- Home
- QS vs PTCT Comparison
QS vs PTCT Comparison
Compare QS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- PTCT
- Stock Information
- Founded
- QS 2010
- PTCT 1998
- Country
- QS United States
- PTCT United States
- Employees
- QS N/A
- PTCT N/A
- Industry
- QS Auto Parts:O.E.M.
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- PTCT Health Care
- Exchange
- QS Nasdaq
- PTCT Nasdaq
- Market Cap
- QS 4.5B
- PTCT 4.1B
- IPO Year
- QS N/A
- PTCT 2013
- Fundamental
- Price
- QS $7.86
- PTCT $57.26
- Analyst Decision
- QS Sell
- PTCT Buy
- Analyst Count
- QS 7
- PTCT 14
- Target Price
- QS $5.90
- PTCT $67.00
- AVG Volume (30 Days)
- QS 16.7M
- PTCT 1.4M
- Earning Date
- QS 10-22-2025
- PTCT 08-07-2025
- Dividend Yield
- QS N/A
- PTCT N/A
- EPS Growth
- QS N/A
- PTCT N/A
- EPS
- QS N/A
- PTCT 7.72
- Revenue
- QS N/A
- PTCT $1,764,929,000.00
- Revenue This Year
- QS N/A
- PTCT $119.89
- Revenue Next Year
- QS N/A
- PTCT N/A
- P/E Ratio
- QS N/A
- PTCT $7.52
- Revenue Growth
- QS N/A
- PTCT 96.00
- 52 Week Low
- QS $3.40
- PTCT $30.41
- 52 Week High
- QS $15.03
- PTCT $58.73
- Technical
- Relative Strength Index (RSI)
- QS 43.23
- PTCT 69.70
- Support Level
- QS $7.40
- PTCT $48.96
- Resistance Level
- QS $8.15
- PTCT $50.70
- Average True Range (ATR)
- QS 0.41
- PTCT 2.23
- MACD
- QS -0.05
- PTCT 0.95
- Stochastic Oscillator
- QS 26.61
- PTCT 86.38
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.